Assessment of Generic Drug Supply Efforts Published

Overview

The Ministry of Health, Labour and Welfare compiled and published the assessment results on efforts by companies marketing generic drugs to ensure a stable supply, as part of the FY2026 drug price revision. In response to supply concerns triggered by quality misconduct and other issues, and based on discussions by a review panel, the assessment evaluates company efforts to ensure a stable supply of quality-assured medicines. The ministry had planned to publish assessment results from FY2026 onward. It says it will continue to advance measures needed to ensure a stable supply of generic drugs.

This summary was automatically generated by AI. Please refer to the original article for accuracy.

Key points

  • The Ministry of Health, Labour and Welfare published the assessment results for the FY2026 drug price revision.
  • The assessment covers company efforts to ensure quality and a stable supply.
  • The policy was to publish assessment results from FY2026 onward, and the results have now been published.

Overview

In response to supply concerns triggered by quality misconduct and other issues, the Ministry of Health, Labour and Welfare established a framework for assessing company efforts, based on discussions by the Review Panel on the Ideal Industrial Structure for Ensuring a Stable Supply of Generic Drugs and other deliberations.

Details

The assessment covers efforts by companies marketing generic drugs as part of the FY2026 drug price revision. It evaluates efforts to ensure a stable supply of quality-assured medicines. Under the policy to publish results from FY2026 onward, the ministry has now compiled and published the assessment results.

The Ministry of Health, Labour and Welfare says it will advance necessary measures to ensure that generic drugs continue to be supplied stably.

Related Articles